pharmaphorum

NOVEMBER 23, 2021

Sanofi is the first pharma company to partner with Baidu on its LinearDesign AI platform, which has been developed specifically to optimise the sequence of mRNA-based vaccines and drugs. billion earlier this year. Specific financial terms have not been disclosed.

Licensing 105

Licensing Licensing Vaccination Vaccine 105

pharmaphorum

FEBRUARY 14, 2022

Seattle, US vaccine startup Curevo has raised $60 million in first-round financing that it says will be used to run head-to-head trials of its experimental shingles vaccines CRV-101 and GlaxoSmithKline’s market-leading Shingrix. The biotech has been looking for a development partner for the shot as a chickenpox vaccine.

Vaccination 52

Vaccination Vaccine Immune Response Trials 52

pharmaphorum

FEBRUARY 18, 2021

The South African coronavirus variant may cut the effectiveness of Pfizer/BioNTech’s vaccine by around two thirds, according to a laboratory study. Mutations may alter neutralisation by affecting spike function rather than antigen response and its also unclear from this study how the T-cell response is affected.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

The Pharma Data

DECEMBER 11, 2020

The University of Oxford has regularly appeared in our updates since July 2020, as its team of researchers leads an ongoing clinical trial for the Covid-19 vaccine. More recently, the university has released news of its collaboration with Thermo Fisher Scientific as it looks to discover an immune Covid-19 response pre- and post-vaccination.

Antibody 52

Antibody Vaccination Vaccine Containment 52

The Pharma Data

NOVEMBER 27, 2020

Vaccine development to cure coronavirus is at an all-time high after Pfizer and BioNTech announced they had success with a possible vaccine candidate. One dose of the Sputnik V vaccine will cost less than $10 for international markets.

Vaccination 52

Vaccination Vaccine Immune Response Marketing 52

pharmaphorum

SEPTEMBER 23, 2021

AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19. The company sees its deal with VaxEquity as going well beyond COVID-19, extending into other vaccines as well as therapeutic drugs.

RNA 52

RNA Immune Response Vaccination Vaccine 52

XTalks

AUGUST 18, 2021

While infectious disease experts and drug companies have rightfully spent the last 18 months developing therapeutics and vaccines targeting SARS-CoV-2 and COVID-19, another global threat to public health — antimicrobial resistance (AMR) — has, and will continue to, persist until similar direct action is taken. That is, until now.

Development 105

Development Bacteria Drugs Vaccination 105

XTalks

AUGUST 17, 2020

chimeric receptor antigen [CAR] T cell) immune modulators (i.e. protein-based biologics) and vaccine treatments. Immune checkpoint inhibitors : these are drugs that block immune checkpoints, allowing immune cells to elicit enhanced responses to cancer cells. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

AUGUST 13, 2020

In 2018 the research firm Reputation Institute ranked Pfizer’s reputation at rock bottom on a list of 22 pharma companies – and none of them ranked highly against other sectors! Pfizer has four different mRNA platform vaccines in play against one-another: a radical new approach for them.

Branding 112

Branding Vaccination Vaccine Filler 112

World of DTC Marketing

AUGUST 6, 2020

million people have been infected and nearly 155,000 have died, the promise of that vaccine is hampered by a vexing epidemic that long preceded Covid-19: obesity. Of course, there is no ROI in providing people with health information that can use but it would show that pharma companies are interested in the welfare of people versus profits.

Doctors 180

Doctors Doctor Immune Response Vaccination 180

XTalks

MARCH 11, 2025

Advances in mRNA quantification are paving the way for improved vaccine analytics a critical component as the industry shifts toward multivalent mRNA vaccines. These vaccines can be engineered to address antigenic variability and stimulate a wide-ranging immune response.

Vaccine 64

Vaccine Vaccination Development Manufacturing 64

World of DTC Marketing

SEPTEMBER 28, 2020

J&J’s COVID vaccine is being promoted by the media to have a 98% immune system response. Will it lead to an early approval with limited testing or will J&J ensure the vaccine goes thru thorough testing? government to manufacture 100 million doses of its investigational COVID-19 vaccine.

Vaccine 163

Vaccine Vaccination Clinical Trials Clinical Trials 163

Roots Analysis

JANUARY 27, 2025

It is important to note that, for the purpose of subcutaneous biologics market analysis, the biologics were segregated into antibodies , nucleotides, proteins and vaccines. Moreover, protein-based drugs are also well tolerated inside the body, thereby reducing the chances of causing any immune response in the body.

Marketing 40

Marketing Drug Delivery Development Protein 40